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Long-Term Cardiac Function After Peripartum Cardiomyopathy and
Preeclampsia: A Danish Nationwide, Clinical Follow-Up Study Using
Maximal Exercise Testing and Cardiac Magnetic Resonance Imaging
Anne S. Ersbøll, MD, PhD; Annemie S. Bojer, MD; Maria G. Hauge, MD; Marianne Johansen, MD, PhD, MSHS-CML;
Peter Damm, MD, DMSc; Finn Gustafsson, MD, DMSc; Niels G. Vejlstrup, MD, PhD
Background-—Long-term clinical studies of peripartum cardiomyopathy (PPCM) are few. We aimed to measure the long-term effect
of PPCM on cardiac function in comparison with the long-term effects of severe preeclampsia and uncomplicated pregnancy.
Methods and Results-—A nationwideDanish cohort of women diagnosedwith PPCM from2005 to 2014 (PPCMgroup) were invited to
participate in a clinical follow-up study including maximal cardiopulmonary exercise testing and cardiac magnetic resonance imaging.
Matched women with previous severe preeclampsia (preeclampsia group) and previous uncomplicated pregnancies (uncomplicated
pregnancies group) served as comparison groups. A total of 84 women with 28 in each group participated. Median time to follow-up
after PPCM was 91 months. Most women (85%) in the PPCM group reported no symptoms of heart failure. Mean left ventricular
ejection fraction in the PPCM group was normal at 62%, but signiﬁcantly lower than in the preeclampsia group and the uncomplicated
pregnancies group where mean left ventricular ejection fraction was 69% and 67%, respectively (P<0.0001). Women in the PPCM
group also had impaired diastolic function with reduced left ventricular peak ﬁlling rate, left atrial passive emptying volume, and left
atrial passive emptying fraction. Maximal exercise capacity (peak VO2) was also reduced in the PPCM group compared with the
preeclampsia group and the uncomplicated pregnancies group, and PPCM, high body mass index, and low left ventricular ejection
fraction independently predicted reduced peak VO2. Only 1 woman with PPCM had late gadolinium enhancement.
Conclusions-—Women generally recovered left ventricular ejection fraction and were asymptomatic 7 years after PPCM, but had
subtle diastolic dysfunction on cardiac magnetic resonance imaging and reduced peak VO2. Focal myocardial ﬁbrosis assessed
with late gadolinium enhancement was, however, uncommon. ( J Am Heart Assoc. 2018;7:e008991. DOI: 10.1161/JAHA.118.
008991.)
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P eripartum cardiomyopathy (PPCM) is deﬁned as idio-pathic heart failure with left ventricular ejection fraction
(LVEF) reduced below 45% in late pregnancy or in the ﬁrst
months after childbirth in women with no previous heart
disease or other identiﬁable causes of heart failure.1
Incidence varies greatly worldwide, most likely reﬂecting
differences in population ethnicity, awareness of the disease,
and rigor of deﬁnition.2
PPCM is associated with hypertensive disorders of preg-
nancy (HDP), including chronic hypertension, gestational
hypertension, and preeclampsia.3 Recent studies report an
incidence of concomitant HDP in nearly half of PPCM cases.4–7
This clinical association may be explained by shared patho-
physiological mechanisms such as increased levels of soluble
Fms-like tyrosine kinase (sFlt-1).8,9 Higher sFlt-1 levels seem to
correlate with severity of both preeclampsia10 and PPCM,11 and
echocardiographic studies have also demonstrated subclinical
cardiac dysfunction in women with preeclampsia,12 leading to
the hypothesis that preeclampsia and PPCM represent a
spectrum of disease.2,8 Some PPCM studies have reported
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better 6- to 12-month outcome associated with concomitant
HDP,5,6,13 but the clinical and prognostic implications of
concomitant HDP are not clear: In the multicenter IPAC
(Investigations in Pregnancy-Associated Cardiomyopathy)
cohort, hypertension did not predict LVEF at 12-month follow-
up,4 whereas Lindley et al recently noted increased
morbidity andmortality among PPCMwomen with concomitant
preeclampsia compared with PPCM women without
preeclampsia.7 The impact of concomitant HDP on long-term
outcome is unknown.
We hypothesized that women with previous PPCM and
women with previous severe preeclampsia have graded
degrees of cardiovascular dysfunction at long-term follow-up
compared with women with uncomplicated pregnancies. We
aimed to invite all women diagnosed with PPCM in
Denmark from 2005 to 2014 to a clinical follow-up study
in order to measure (1) systolic and diastolic cardiac
function using cardiac magnetic resonance imaging (CMR)
and (2) exercise capacity deﬁned as peak oxygen con-
sumption (peak VO2) during maximal exercise testing, and
compare the ﬁndings with 2 age-matched groups of women
with either previous severe preeclampsia or previous
uncomplicated pregnancies.
Methods
Study Population
Three groups of age-matched women were invited by letter to
participate:
1. Women with previous PPCM (PPCM group).
2. Women with a history of severe preeclampsia without
cardiac complications (PE group).
3. Women with a history of uncomplicated pregnancies (UCP
group).
The PPCM group was recruited from a nationwide Danish
cohort of 61 women with a validated PPCM diagnosis during
2005–2014, as previously described.6 Women in the PE group
and the UCP group were identiﬁed in an obstetric database
that covers deliveries in the Capital Region of Denmark and
accounts for approximately one third of all deliveries in
Denmark.14 These women either had an International Classi-
ﬁcation of Diseases, Tenth Revision (ICD-10) diagnosis of
severe preeclampsia (O14.1) or no diagnoses that indicated
complications during their past pregnancy.
For women in the PE group who agreed to participate, we
reviewed charts to preclude heart failure or other cardiac
complications and validate the diagnosis according to the
American College of Obstetricians and Gynecologists’ Task
Force on Hypertension in Pregnancy.3 Women in the UCP
group verbally conﬁrmed the database information.
The study complies with the Declaration of Helsinki, and
the protocol was approved by the Danish Data Protection
Agency (RH-2016-174, I-Suite 04729) and the Capital
Region’s Committee on Biomedical Research Ethics (H-1-
2014-131). All participants provided written informed
consent.
The data, analytical methods, and study materials will not
be made publicly available to other researchers for purposes
of reproducing the results or replicating the procedure.
Experimental Design and Procedures
All measurements were performed during 1 visit 2 to 11 years
after the index delivery. In sequential order, urine and
nonfasting venous blood samples were collected and height,
weight, and blood pressure were measured. An ECG, exercise
testing, and CMR were then performed. After exercise testing,
the participating women were offered a meal and at least
2 hours of rest before CMR.
Exercise Testing
Maximal cardiopulmonary exercise test, using an upright
exercise bicycle (Ergoselect; Ergoline, Windhagen, Germany),
was performed. After a period of unloaded cycling, the
workload, starting at 50 W, was sequentially increased by
50 W every 2 minutes at speeds of 60 to 80 revolutions per
minute. During the exercise test, women were monitored with
12-lead ECG. The anaerobic threshold was deﬁned as the time
at which the respiratory exchange ratio exceeded 1 without
dropping to levels below 1 during the remaining time of
Clinical Perspective
What Is New?
• In this ﬁrst nationwide, long-term clinical follow-up study of
women with previous peripartum cardiomyopathy, women
generally recovered left ventricular ejection fraction and
were clinically asymptomatic 7 years after diagnosis.
• However, they had diastolic dysfunction, reduced maximal
exercise capacity, and higher body mass index compared
with 2 matched groups of women with either previous
preeclampsia or uncomplicated pregnancies.
What Are the Clinical Implications?
• Despite a symptomatic recovery, some degree of cardiac
dysfunction might persist or relapse late after peripartum
cardiomyopathy.
• Whether this is useful to predict the risk of subsequent
recurrence of heart failure remains unknown and should be
explored in future studies of long-term outcome.
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exercise, and respiratory exchange ratio >1 was used as an
indicator of an adequately performed test. Respiratory gas
analysis was performed using the breath-by-breath technique
(CS-200 Ergospiro, Schiller AG, Baar, Switzerland). At exhaus-
tion, women rated the perceived exertion on the Borg scale,15
maximal workload was noted, and peak oxygen consumption
(peak VO2) was calculated as mL/kg/min (Standard Pressure
Temperature Dry).
Cardiac Magnetic Resonance Imaging
CMR was performed using a 1.5 Tesla magnetic resonance
scanner (GE Optima MR450; GE Healthcare, Waukesha, WI).
Steady-state free precession, end-tidal breath-hold images
were obtained in the 2-, 3-, and 4-chamber views as well as a
transaxial and a short-axis cine stack covering the whole
heart with no gaps (slice thickness 8 mm, echo time 1.6 ms,
ﬁeld of view 320 to 370 mm, resolution matrix 256 9
256 mm, and 25 phases per cardiac cycle). Ten minutes after
an intravenous bolus of gadobutrol (0.15 mmol/kg body
weight, Gadovist; Bayer HealthCare AG, Leverkusen, Ger-
many), the short- and long-axis views were repeated using a
T1-weighted inversion recovery gradient echo sequence to
demonstrate late gadolinium enhancement (slice thickness
8 mm, echo time 2.9 ms, inversion time 300–375 ms, ﬁeld
of view 320–400 mm, and resolution matrix 2569256 mm).
Inversion time was continuously adjusted to null the
myocardial signal.
Ofﬂine image analysis was performed using semiauto-
mated CMR software (cvi42; Circle Cardiovascular Imaging,
Calgary, AB, Canada) for manual tracing of the epi- and
endocardial borders. For segmentation of the left ventricle
(LV), papillary muscles were excluded from LV mass and LV
blood pool.16 LV end-systolic volume, LV end-diastolic volume
(LVEDV), LV peak ﬁlling rate (LVPFR), LV stroke volume, and
LVEF were read from the LV volume-time curve.
Manual tracing of the right ventricle endocardial borders
on the transaxial cine stack in end-systole and end-diastole
were used for determination of right ventricular end-systolic
volume, right ventricular end-diastolic volume, and right
ventricular ejection fraction.
In the segmentation of the left atrium (LA), the left atrial
appendage was included, the pulmonary veins were
excluded,17 and the mitral valve annulus was deﬁned as the
inferior LA border.18 From the transaxial cine stack, the LA
volume-time curve was constructed to asses LV diastolic
function. This enabled determination of LA passive emptying
volume (LAPEV), LA active emptying volume, LA passive
emptying fraction (LAPEF), and LA active emptying fraction19
(Figure S1).
All volumes and LV mass were indexed to body surface
area according to the Mosteller method.
Focal late gadolinium enhancement (LGE) was considered
as myocardial areas of high signal intensity (>5 SDs) and
required conﬁrmation in 2 orthogonal planes.20
LVEF estimated by echocardiography 12 months after
diagnosis was available from chart reviews that were part of
the parent cohort study,6 where complete recovery was
deﬁned as LVEF ≥55% 12 months after the initial diagnosis.
Improvement in LVEF from 12 months after diagnosis to
participation was deﬁned as ≥10% increase in LVEF. Corre-
spondingly, deterioration was deﬁned as ≥10% decrease in
LVEF at participation.
Statistical Analyses
Data are presented as numbers and proportions for
categorical data, as means and SDs for normally distributed
continuous data, and as medians and ranges for non-
normally distributed continuous data. Categorical data were
compared between groups using chi-square test or Fisher’s
exact test, as appropriate. Continuous characteristics and
outcome were compared between the 3 study groups using
the ANOVA test in the case of normal distribution and the
Kruskal–Wallis test in the case of non-normal distribution.
Continuous data were compared between 2 groups (all
women with PPCM included in the main cohort by partici-
pation in the follow-up study or not, and participating women
in the PPCM group by concomitant HDP or not) by t test or
Mann–Whitney U test, as appropriate. P<0.05 was consid-
ered statistically signiﬁcant.
Some post-hoc analyses were made: First, we performed
multiple comparisons of outcome variables that were signif-
icant in the global ANOVA or Kruskal–Wallis tests using chi-
square test, Fisher’s exact test, Student t test, or Mann–
Whitney U test, as appropriate. To correct for multiple
comparisons, the Bonferroni method was applied and level of
signiﬁcance in these post-hoc analyses was deﬁned as 0.05
divided by the number of comparisons per outcome (3) as we
compared the PPCM group with the PE group and the UCP
group, respectively, as well as the PE group with the UCP
group, and by the number of dependent outcome variables
examined (20). Thus, level of signiﬁcance was deﬁned as
0.05/(3920)=0.0008. Second, analysis of covariance of key
outcome variables was performed in order to report differ-
ences in means between the 3 study groups, adjusted for
body mass index (BMI) and age. Furthermore, a multiple linear
regression analysis was performed to assess the effect of
selected candidate variables of clinical importance with a
likely impact on peak VO2 among all women, who completed
the exercise test. The variables chosen were: time to follow-
up, BMI at follow-up, age at follow-up, current use of beta-
blockers, time spent on exercise weekly, LVEF at follow-up,
and, as a marker of diastolic function, LVPFR/LVEDV ratio.
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We included only 1 marker of diastolic function to avoid
colinearity, and we chose LVPFR/LVEDV ratio, because it is
more easily obtained and clinically accessible than markers
such as LAPEV and LAPEF that both require recordings and
analysis of LA images.
Author A.S.E. had full access to all data and takes
responsibility for its integrity and the data analysis. Because
of the sensitive nature of the data collected for this
study, requests to access the data set from qualiﬁed
researchers trained in human subject conﬁdentiality protocols
may be sent to the authors at the Center for Pregnancy
and Heart Disease, Copenhagen University Hospital Rigs-
hospitalet (Copenhagen, Denmark) at ajoe0026@regionh.dk
or nvej0001@regionh.dk.
All statistical analyses were performed using SAS Enter-
prise Guide software (version 7.1; SAS Institute Inc, Cary, NC).
Results
Of 61 women in the parent PPCM cohort, 2 had died, both
within a year after the diagnosis, and another was lost to
follow-up because of emigration. Of the remaining 58 women,
28 agreed to participate (48%). Among eligible women with
PPCM, more participating women were of white race, whereas
disease severity and incidence of major adverse events did
not differ signiﬁcantly between participants and decliners
(Table S1). A total of 94 women with previous preeclampsia
were invited by letter in order to recruit 28 participants in this
PE group (30%), and 129 women with a previous uncompli-
cated pregnancy were invited in order to recruit 28 women in
this UCP group (22%). The 3 groups of participants did not
differ signiﬁcantly from one another in terms of age, race,
smoking habits, comorbidities, self-reported exercise routi-
nes, or time from index delivery to follow-up (Table 1 and
Table 1. Distribution of Baseline Characteristics Among All Participants in the Index Pregnancy and at Study Participation
Peripartum
Cardiomyopathy,
n=28
Preeclampsia,
n=28
Controls,
n=28 P Value*
Index pregnancy characteristics
Age at delivery, y 30.7 (6.0) 30.5 (5.0) 31.0 (5.2) 0.73
Race, n (%)
White 28 (100) 28 (100) 27 (96) 0.364
Black 0 0 1 (4)
Body mass index, kg/m2 28.3 (6.4) 22.8 (3.2) 21.3 (1.8) <0.0001
Concomitant HDP, n (%)
Gestational hypertension 2 (7) 0 0
Preeclampsia 11 (39) 28 (100) 0
HELLP 2 (7) 0 0
Follow-up characteristics
Age, y 38.0 (6.9) 39.1 (5.3) 38.8 (5.6) 0.754
Median time from index delivery
to follow-up (range), mo
91 (227–137) 95 (26–143) 101 (25–146) 0.603
Engaged in exercise, n (%) 20 (71) 26 (93) 25 (89) 0.060
Median weekly exercise (range), h 2 (0–14) 5.5 (0–20) 4 (0–8) 0.031
NYHA class, n (%)
I 24 (86) 28 (100) 28 (100)
II 3 (11) 0 0 0.078
III 1 (3) 0 0
Current antihypertensive/heart
failure medication†, n (%)
13 (46) 3 (11) 0 <0.0001
Body mass index, kg/m2 30.0 (8.4) 23.3 (4.1) 22.6 (3.0) <0.001
Data are presented as meansSDs, unless otherwise stated. HDP indicates hypertensive disorders of pregnancy; HELLP, hemolysis elevated liver enzymes low platelets syndrome; NYHA,
New York Heart Association.
*Global analyses of difference between means, medians, and proportions across the 3 groups were performed by ANOVA, Kruskal–Wallis, or chi-square test, respectively.
†Daily antihypertensive/heart failure medications: angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, beta-blockers, calcium antagonists, and diuretics.
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Table S2). Median time to follow-up from index delivery was
91 months for the PPCM group, 95 months for the PE group,
and 101 months for the UCP-group. There were more
nulliparous women, more caesarean deliveries, and earlier
mean gestational age at time of delivery in the PE group,
whereas fewer women in the PPCM group started breast-
feeding and breastfed for a shorter period of time. Women in
the PPCM group had higher BMI and reported less time spent
on exercise at follow-up compared with the other 2 groups.
They also used more antihypertensive/heart failure medica-
tions: 11 women (43%) were still on daily medication at study
participation. No women in the PPCM group received
bromocriptine therapy as previously reported.
Eight women in the PPCM group (29%) had ECG abnor-
malities at follow-up (Table S3). A normal ECG did not exclude
the cardiac functional abnormalities described below.
Exercise Testing
Four women in the PPCM-group did not participate in exercise
testing because of extreme obesity (BMI >60 kg/m2), phys-
ical inability caused by concomitant multiple sclerosis
Table 2. Exercise Testing and Cardiac Magnetic Imaging Findings at Study Participation
Peripartum
Cardiomyopathy Preeclampsia Controls P Value*
Exercise testing n=24 n=28 n=27
Peak VO2, mL/kg/min 29.6 (7.2)
†‡ 43.2 (11.1) 45.4 (10.2) <0.0001
Heart rate at rest, bpm 72 (17) 68 (7) 69 (10) 0.418
Heart rate at peak, bpm 168 (19) 167 (19) 176 (16) 0.185
Systolic BP at rest, mm Hg 129 (16) 129 (16) 119 (11) 0.019
Diastolic BP at rest, mm Hg 83 (14) 82 (10) 73 (9) 0.007
Systolic BP at peak, mm Hg 185 (38) 182 (30) 179 (21) 0.759
Diastolic BP at peak, mm Hg 92 (27) 94 (18) 99 (23) 0.571
Perceived exertion, Borg scale 18 (1) 18 (1) 17 (1) 0.752
Respiratory exchange ratio 1.04 (0.14) 1.03 (0.11) 1.00 (0.11) 0.496
Peak workload, W 179 (30) 208 (34) 207 (37) 0.004
Cardiac magnetic resonance imaging n=25 n=27 n=27
Left ventricular parameters
Left ventricular ejection fraction, % 62 (6)†‡ 69 (4) 67 (5) <0.0001
LVEDV, mL/m2 84 (14) 78 (10) 80 (10) 0.233
Left ventricular end-systolic volume, mL/m2 31 (7) 25 (8) 27 (6) 0.008
Median left ventricular mass (range), g/m2 62 (43–143) 60 (48–86) 57 (44–74) 0.205
LVPFR, mL/s per m2 229 (49) 276 (57) 265 (45) 0.005
Left atrial volumes
Left atrial passive emptying volume, mL/m2 13 (5)†‡ 19 (4) 20 (3) <0.0001
Left atrial active emptying volume, mL/m2 11 (4) 9 (2) 9 (2) 0.129
LVPFR/LVEDV ratio 2.8 (0.6)† 3.5 (0.6) 3.2 (0.6) <0.0001
Left atrial passive emptying fraction, % 34 (10) 40 (8) 42 (8) 0.002
Left atrial active emptying fraction, % 38 (9) 35 (9) 35 (8) 0.359
Data are presented as meansSDs, unless otherwise stated. BP indicates blood pressure; LVEDV, left ventricular end-diastolic volume indexed to body surface area; LVPFR, left ventricular
peak ﬁlling rate indexed to body surface area.
*Global analyses of difference between means, medians, and proportions across the 3 groups were performed by ANOVA, Kruskal–Wallis, or chi-square test, respectively. P<0.05 was
considered statistically signiﬁcant.
†PPCM group signiﬁcantly different compared with the preeclampsia group. Post-hoc analyses were performed by Student t test, Mann–Whitney U test, or chi-square test, as appropriate.
P<0.05/(3920)=0.0008 was considered statistically signiﬁcant.
‡PPCM group signiﬁcantly different compared with the uncomplicated control group. Post-hoc analyses were performed by Student t test, Mann–Whitney U test, or chi-square test, as
appropriate. P<0.05/(3920)=0.0008 was considered statistically signiﬁcant.
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developed after PPCM onset, white coat hypertension with in-
hospital resting systolic blood pressure >200 mm Hg, and
technical problems with the equipment. Also, 1 woman in the
UCP group did not complete the exercise test because of
technical problems. The 2 women who experienced technical
problems were offered new appointments to redo the test, but
were both unable to attend a new appointment within the
study period. Overall, women in the PPCM group had
signiﬁcantly lower peak VO2 compared with women in the
PE group and the UCP group (Table 2). Mean peak VO2 was
29.6, 43.2, and 45.4 mL/kg/min, respectively (P<0.0001).
Despite an overall high perceived exertion on the Borg scale,
not all women reached the anaerobic threshold. Among
women who reached the anaerobic threshold, peak VO2 was
still signiﬁcantly lower in the PPCM group: Mean peak VO2
was 29.1, 43.5, and 46.0 mL/kg/min, respectively
(P<0.0001). After adjusting for BMI and age, this difference
was attenuated (P=0.071; Table 3). Additional adjustment for
amount of time spent on exercise weekly did not change the
result (analysis not shown).
Cardiac Magnetic Resonance Imaging
Three women in the PPCM group did not undergo CMR: 2 had
implantable cardioverter deﬁbrillator units incompatible with
magnetic resonance imaging and 1 because of claustropho-
bia. Both in the PE group and in the UCP group 1 participant
also could not complete the CMR protocol because of
claustrophobia. The 25 women in the PPCM group, who
underwent CMR, had lower mean LVEF compared with the
other 2 study groups: Mean LVEF was 62% in the PPCM group,
69% in the PE group, and 67% in the UCP group (P<0.0001;
Table 2).
Out of the 25 women in the PPCM group who underwent
CMR, 9 (36%) had further improved their LVEF after
12 months, 16 women (64%) had a stable LVEF, and no one
deteriorated. The 3 women in the PPCM group, who did not
undergo CMR, all had an available echocardiographic LVEF
assessment within 6 months from their study participation:
The 2 women with implantable cardioverter deﬁbrillator units
both had a reduced LVEF of 45% and 20%, respectively,
whereas the third woman had an LVEF of 55%.
Mean LVEF at baseline, after 12 months and at last follow-
up (study CMR or echocardiography within 6 months before
study enrollment), was 279%, 529%, and 6010%,
respectively (Figure).
Diastolic left ventricular function was affected in women in
the PPCM group because both mean LVPFR and mean LAPEV
were lower in this group. Mean LVPFR was 229 mL/s/m2 in
the PPCM group, 276 mL/s/m2 in the PE group, and
265 mL/s/m2 in the UCP group (P=0.005). Mean LAPEV
was 13, 19, and 20 mL/m2, respectively (P<0.0001). Also,
LVPFR/LVEDV ratio was signiﬁcantly lower in the PPCM group
(Table 2). After adjusting for BMI and age, differences in mean
systolic (LVEF) and some diastolic functional parameters
(LVPFR/LVEDV ratio and LAPEV) remained signiﬁcantly
different between the 3 groups (Table 3).
In a multiple linear regression analysis of peak VO2 among
all 79 women who completed the maximal exercise test, BMI,
PPCM, and LVEF all independently predicted peak VO2 after
adjusting for time to follow-up, age, current use of beta-
blockers, amount of time spent on exercise weekly, and
LVPFR/LVEDV ratio (Table 4).
Only 1 woman with PPCM (4%) and no women in the other
2 groups had LGE. The woman who had LGE had concomitant
preterm preeclampsia and a baseline LVEF of 35%, improving
to 45% after 7 months and 73% after 42 months. LGE pattern
was multifocal with both midwall, transmural, and epicardial
foci. The left ventricle was moderately dilated (LVEDV index
119 mL/m2), and left myocardial mass was hypertrophic
Table 3. Difference in Means (95% Conﬁdence Interval) of Key Outcome Variables in the 3 Study Groups Adjusted for Body Mass
Index and Age at Follow-up
UCP Group
(Reference) PE Group PPCM Group P Value
Peak VO2, mL/kg/min  0.34 (4.92 to 4.23) 6.17 (11.87 to 0.47) 0.071
Left ventricular ejection fraction, %  2.11 (0.41 to 4.63) 7.31 (10.51 to 4.11) <0.0001
Left ventricular peak filling rate, mL/s/m2  23.83 (3.52 to 51.18) 14.33 (49.03 to 20.36) 0.053
LVPFR/LVEDV ratio  0.31 (0.01 to 0.62) 0.56 (0.95 to 0.17) <0.0001
Left atrial passive emptying volume, mL/m2  1.13 (3.43 to 1.18) 4.92 (7.82 to 2.02) 0.004
Left atrial passive emptying fraction, mL/m2  1.66 (6.33 to 3.01) 6.79 (12.66 to 0.91) 0.074
Systolic blood pressure at rest, mm Hg  9.87 (2.48–17.3) 5.75 (3.47 to 15.0) 0.034
Diastolic blood pressure at rest, mm Hg  8.36 (2.47–14.24) 7.22 (0.12 to 14.55) 0.017
LVEDV indicates left ventricular end-diastolic volume; LVPFR, left ventricular peak ﬁlling rate; PE, preeclampsia; PPCM, peripartum cardiomyopathy; UCP, uncomplicated pregnancy.
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(mass index of 143 g/m2), but wall thickness was nowhere
≥15 mm, and the woman did not meet the criteria for
hypertrophic cardiomyopathy. She had no family history of
cardiomyopathy and no initial major adverse events in terms
of need of inotropic therapy, mechanical circulatory support,
or prolonged need for intensive care, but had a stroke 2 years
after the PPCM diagnosis.
Right ventricular volumes and systolic function did not
differ between the 3 groups (Table S3).
There were 15 participants in the PPCM group who had
concomitant HDP (54%) and 13 who did not (46%). Of the
15 women with concomitant HDP, 12 had preeclampsia and
3 had gestational hypertension. Women who had concomi-
tant HDP had signiﬁcantly higher systolic and diastolic
blood pressure at rest. They also had signiﬁcantly higher LA
active emptying fraction, and LAPEF was correspondingly
lower, but this did not reach statistical signiﬁcance
(Table 5).
In a subanalysis, we compared peak VO2 and diastolic and
systolic functional parameters among those women diag-
nosed with PPCM who reported to be free from heart failure
symptoms at study participation (New York Heart Association
class I, n=24) with the 2 other groups. Differences in peak
VO2, LVEF, LVPFR, LAPEV, and LAPEF persisted, whereas
LVEDV did not differ between the 3 groups in this analysis
(not shown).
Discussion
In this Danish nationwide study of the long-term effect of
PPCM on cardiac structure and function, we observed a
high rate of recovery of LV systolic function with a mean
LVEF of 62% and the majority of patients (85%) reporting
to be free from heart failure symptoms. Women in the
PPCM group, however, had evidence of left ventricular
diastolic dysfunction and much lower exercise capacity
compared with those in the PE group and in the UCP
group. PPCM, high BMI, and low LVEF were independent
predictors of reduced peak VO2 overall. LGE was uncom-
mon in this cohort of women with PPCM and only noted in
1 of 25.
The notion of delayed recovery beyond the early phase is in
accord with other studies, showing further increased recovery
rates after 12 compared with 6 months4,13 and, in 1 study, an
average time to recovery of 19 months.21 Barasa et al
recently reported on 24 Swedish women with PPCM and a
mean follow-up time for echocardiography of 2.1 years, and
found that the majority recovered with 54% early recovery
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Figure. Changes in left ventricular ejection fraction. Left ventricular ejection fraction at diagnosis, at
12 months and at study visit among 28 women with peripartum cardiomyopathy. Mean with 95%
conﬁdence interval in bold.
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before 100 days after diagnosis and further 21% late
recovery.22
In a study of 71 Chinese PPCM women with a mean time to
follow-up of 4333 months, 44% had persistently left
ventricular systolic dysfunction at follow-up.23 In our study,
we noted a higher recovery rate with only 2 of 28 women (7%)
having LVEF <50% after a median of 91 months, but similar to
Li et al, we did not observe any differences in long-term LV
systolic function between women with and without concomi-
tant HDP. In an American cohort of 39 predominantly black
women with PPCM, concomitant preeclampsia was identiﬁed
in 44% and was associated with higher 1-year mortality and
more hospital readmissions.7 This contrasts with the ﬁndings
in our primarily white parent PPCM cohort, where all major
adverse events occurred in women without HDP.6 Despite the
higher early mortality and morbidity observed by Lindley et al,
they found a higher mean LVEF at 1-year follow-up in the
group with concomitant preeclampsia whereas persistent
diastolic dysfunction was common in both groups, similar to
our ﬁndings.
In order to explain these conﬂicting reports on the effect of
concomitant preeclampsia on PPCM, race and genetics must
be taken into account. It has previously been shown that race
affects outcome and severity of both preeclampsia and PPCM,
with black women experiencing more-severe disease.4,24,25
Mutations in the TTN gene, encoding the cardiac sarcomere
protein, titin, have been found in a subgroup of 15% of women
with PPCM, predominantly in black women who did not have
concomitant HDP. Black women with TTN mutations had a
lower LVEF after 12 months compared with black women
without TTN mutations, whereas this difference was not
observed among women of white descent.25 The different
impact of concomitant HDP observed in the 2 studies of
primarily black and white women thus could reﬂect different
genetic susceptibilities to, for example, sFlt-1–mediated
endothelial injury.8
In our study, subtle diastolic dysfunction was present in
the setting of LVEF recovery. Residual myocardial injury
correlating modestly with sFlt-1 levels have been described
previously.26 Whether persistent diastolic dysfunction as
assessed by CMR is related to sFlt-1 and other biomarkers
associated with PPCM and HDP is currently unknown.
Exercise capacity was signiﬁcantly reduced in women in
the PPCM group, who largely reported to be free from heart
failure symptoms. Also, physical activity was lower and BMI
higher in the PPCM group compared with women in the PE
group and in the UCP group. This may reﬂect exercise
intolerance attributed to diastolic dysfunction, which may
again precede symptomatic heart failure with preserved
ejection fraction. Heart failure with preserved ejection fraction
occurs more often in women and is thought to be the result of
a systemic proinﬂammatory state with microvascular
endothelial inﬂammation similar to that of preeclampsia.9,27
Diastolic dysfunction expressed as reduced LAPEF has
previously been noted in heart failure with preserved ejection
fraction patients,28 and diastolic dysfunction further corre-
lates with exercise capacity.29 This supports the hypothesis
that the observed reduced exercise capacity in PPCM women
could be related to the diastolic dysfunction observed.
BMI, a well-known predictor of exercise capacity, also in
our study proved to be an independent predictor of exercise
capacity and was signiﬁcantly increased in the PPCM group,
both at the beginning of the index pregnancy and at study
follow-up. We were unable to match the control groups with
the PPCM group on BMI, but in a recent study from Finland,
previously sedentary women with a mean BMI of 26 kg/m2
underwent exercise testing after a 9-week exercise
intervention.30 In terms of BMI, this study population may
be a better comparator to our PPCM group, who reported a
median of 2 hours of weekly exercise. Mean peak VO2 was
38 mL/kg/min in the Finnish group, which is less than our
UCP group but still 25% higher than the PPCM group.
Overweight has not traditionally been listed as a risk factor
for PPCM,1,2 but in a nationwide Swedish study, BMI was
higher in women with PPCM compared with controls,5 and
mean BMI was also above the normal range (26.4 kg/m2) in
Table 4. Multiple Linear Regression Analysis of Predictors of
Maximal Exercise Capacity (Peak VO2) Among All Women Who
Completed the Maximal Exercise Test at Study Participation
(N=79)
b-Value* 95% Conﬁdence Interval P Value
Time to follow-up, mo 0.010 0.056 to 0.077 0.754
Age at follow-up, y 0.330 0.745 to 0.085 0.117
Body mass index
at follow-up, kg/m2
1.228 1.742 to 0.7114 <0.0001
Study group
PPCM group 11.269 18.257 to 4.282
0.008PE group 0.999 5.835 to 3.838
UCP group Reference
Current use of
beta-blockers
4.455 3.817 to 12.728 0.286
Time spent weekly
on exercise, h
0.264 0.283 to 0.881 0.339
Left ventricular
ejection fraction, %
0.517 1.003 to 0.032 0.037
LVPFR/LVEDV ratio 0.990 2.926 to 4.905 0.615
LVEDV indicates left ventricular end-diastolic volume; LVPFR, left ventricular peak ﬁlling
rate; PE, preeclampsia; PPCM, peripartum cardiomyopathy; UCP, uncomplicated
pregnancy.
*The b-value represents the slope of the linear regression or the number of units the
outcome variable (peak VO2) change with a 1-unit change in the predictor variable.
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women from the worldwide EURObservational Research
Programmes’s PPCM registry.31
Echocardiography studies have repeatedly demonstrated
diastolic, and, to some extent, systolic dysfunction in
preeclamptic women and this cardiac impairment may persist
or relapse several years postpartum.12,32 This is the ﬁrst study
to incorporate CMR in this patient group. CMR is more
accurate in terms of volumetric measurements compared with
echocardiography,33 but even with CMR we were unable to
detect any statistically signiﬁcant differences in neither
systolic nor diastolic function between the PE group and the
UCP group after a mean follow-up time of 95 months.
Similar to ﬁndings in the IPAC cohort,34 focal myocardial
ﬁbrosis assessed as LGE was rare and LVEF recovery was high
in our PPCM group. This is in contrast to a German cohort of
34 PPCM women who underwent CMR at the time of
diagnosis and after 5 months, where 71% had LGE.35 In a
smaller study, LGE was found in 4 of 10 women and was
associated with a worse prognosis.36 LGE is associated with a
poorer prognosis in nonischemic cardiomyopathies,37 and its
absence in our study population is reassuring in order to
predict prognosis. But the observed difference in LGE
prevalence after PPCM is still unexplained and should be
explored in future studies that may also include measurement
of diffuse myocardial ﬁbrosis, which is associated with heart
failure with preserved ejection fraction.38
Some limitations of our study must be considered.
Selection bias could have been introduced given that PPCM
Table 5. Characteristics and Clinical Findings in Women With Peripartum Cardiomyopathy by HDP in the Index Pregnancy
HDP No HDP P Value
Characteristics n=15 n=13
LVEF at diagnosis, % 29 (7) 24 (0) 0.113
Median time from index delivery
to follow-up (range), mo
90 (26–143) 104 (25–156) 0.083
Age at follow-up, y 37 (7) 39 (7) 0.470
Median weekly exercise (range), h 3 (1–14) 1 (0–10) 0.410
NYHA functional class at follow-up, n (%)
I 13 (87) 11 (84)
II 2 (13) 1 (8) 0.506
III 0 1 (8)
Current antihypertensive/heart
failure medication, n (%)
5 (33) 7 (54) 0.274
Body mass index at follow-up, kg/m2 28.3 (1.2) 30.1 (1.3) 0.483
Exercise testing n=13 n=11
Peak VO2, mL/kg/min 29 (7) 31 (8) 0.456
Systolic BP at rest, mm Hg 135 (16) 121 (14) 0.019
Diastolic BP at rest, mm Hg 90 (13) 74 (10) 0.0008
Cardiac magnetic resonance imaging n=14 n=11
LVEF, % 63 (6) 61 (6) 0.460
LVEDV, mL/m2 82 (15) 86 (12) 0.538
Left ventricular end-systolic volume, mL/m2 29 (6) 34 (8) 0.153
Median left ventricular mass (range), g/m2 62 (43–143) 62 (47–75) 0.784
LVPFR, mL/min/m2 224 (48) 236 (51) 0.535
Left passive atrial emptying volume, mL/m2 11.8 (5) 15.6 (5) 0.083
Left atrial active emptying volume, mL/m2 12 (4) 10 (3) 0.238
LVPFR/LVEDV ratio 2.8 (0.6) 2.8 (0.7) 0.909
Left atrial passive emptying fraction, % 32 (10) 36 (8) 0.334
Left atrial active emptying fraction, % 42 (8) 34 (9) 0.043
Data are presented as meansSDs, unless otherwise stated. BP indicates blood pressure; HDP, hypertensive disorders of pregnancy; LVEDV, left ventricular end-diastolic volume indexed
to body surface area; LVEF, left ventricular ejection fraction; LVPFR, left ventricular peak ﬁlling rate indexed to body surface area; NYHA, New York Heart Association; RER, respiratory
exchange ratio.
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nonparticipants could have been more affected by the
disease. However, participants and nonparticipants did not
differ signiﬁcantly on baseline characteristics, including
major adverse events. Nine of the 61 women in the parent
cohort suffered a major adverse outcome, as previously
reported.6 All these events occurred within 12 months after
diagnosis, but upon review of charts for validation of the
PPCM diagnosis and additional data collection, we screened
all available chart notes up to 2016 for any major adverse
events and did not ﬁnd any beyond 12 months. Also, no
additional deaths were noted in the Causes of Death
Register beyond 12 months. The study design of a nation-
wide population-based PPCM cohort reduces the risk of
selection bias that is more signiﬁcant in, for example,
tertiary, single-center cohorts. Our study reports on a white
cohort, and the results may potentially not be extrapolated
to women of black descent. Finally, complete blinding of
CMR analyses was not possible in our study setting, which
may be a source of bias.
Conclusion
In this nationwide long-term follow-up of Danish PPCM
patients, the majority experienced recovery of LV systolic
function. However, subtle diastolic dysfunction on CMR
imaging and markedly reduced peak VO2 were common in
PPCM patients and uncommon in women with previous severe
preeclampsia. Improvement in LV systolic function can be
expected for several years after PPCM. Focal myocardial
ﬁbrosis assessed with LGE was uncommon in this cohort.
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Table S1. Characteristics of women with peripartum cardiomyopathy by participation in the clinical 
follow-up study. 
 Participated in study 
follow-up, n=28 
Did not participate in 
study follow-up, n=33 
P value 
Age at index delivery, 
years  
30.7 (6.0) 32.4 (6.5) 0.294 
Race, n (%): 
Caucasian 
Other (black, Asian or 
Inuit) 
 
28 (100) 
 
0 
 
27  (82) 
 
6 (18) 
 
0.018 
 
Body mass index at the 
beginning of index 
pregnancy, kg/m2 
 
28.3 (6.4) 
 
25.3 (6.1) 
 
0.063 
Year of PPCM 
diagnosis, n (%): 
2005 
2006 
2007 
2008 
2009 
2010 
2011 
2012 
2013 
2014 
 
 
2 (7) 
2 (7) 
4 (13) 
5 (18) 
5 (18) 
3 (11) 
1 (4) 
3 (11) 
1 (4) 
2 (7) 
 
 
5 (15) 
3 (9) 
2 (6) 
5 (15) 
3 (9) 
2 (6) 
3 (9) 
4 (13) 
1 (3) 
5 (15) 
 
 
 
 
 
 
0.741 
Any diabetes, n (%) 3 (11) 3 (9) 0.832 
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Hypertensive disorder of 
pregnancy, n (%) 
 
15 (54) 
 
18 (55) 
 
0.939 
Timing of PPCM 
diagnosis, days from 
delivery 
 
28 (43) 
 
23 (46) 
 
0.962 
LVEF at diagnosis, % 26.7 (8.8) 26.7 (9.3) 0.983 
Major adverse event*, n 
(%) 
 
4 (14) 
 
5 (15) 
 
0.924 
Complete recovery of 
LVEF after 12 months†, 
n (%) 
 
19 (68) 
 
22 (67) 
 
0.921 
 
Data are presented as means ± standard deviations unless otherwise stated.  
PPCM, peripartum cardiomyopathy; LVEF, left ventricular ejection fraction 
*Major adverse events included death, heart transplantation, mechanical circulatory assist device or 
persistent heart failure with LVEF < 35 % after 12 months. 
†Complete recovery of LVEF after 12 months was defined as LVEF ≥ 55 % 
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Table S2. Distribution of additional baseline characteristics among all participants in the index pregnancy 
and at study participation. 
 Peripartum 
cardiomyopathy, 
n=28 
Preeclampsia, 
 
n=28 
Controls, 
 
n=28 
P value*  
Index pregnancy 
characteristics 
    
Early HDP†, n (%) 3 (20) 13 (46) 0 0.231 
Any diabetes, n 
(%) 
3 (11) 0 0 0.045 
Other 
comorbidities‡,  
n (%) 
 
8 (29) 
 
4 (14) 
 
8 (29) 
 
0.350 
Parity, n (%):     
0 12 (43) 24 (86) 12 (43)  
1 11 (39) 3 (11) 10 (36) 0.007 
≥ 2 5 (18) 1 (3) 4 (21)  
Twin pregnancies, 
n (%) 
 
1 (4) 
 
6 (22) 
 
2 (7) 
 
0.063 
Median gestational 
age at delivery 
(range), days 
 
274 (181-294) 
 
256 (168-287) 
 
280 (215-291) 
 
< 0.0001 
Delivery mode,      
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n (%): 
Vaginal delivery 12 (43) 8 (29) 25 (89) < 0.0001 
Caesarean section 16 (57) 20 (71) 3 (11) < 0.0001 
Started 
breastfeeding,  
n (%) 
 
17 (61) 
 
24 (86) 
 
28 (100) 
 
0.0005 
Median duration of 
any breastfeeding 
(range), days 
 
60 (3-300) 
 
158 (30-540) 
 
300 (30-450) 
 
< 0.0001 
Follow-up 
characteristics 
    
Smoking, n (%) 5 (18) 7 (25) 6 (21) 0.685 
Any 
comorbidities§, n 
(%) 
 
14 (50) 
 
9 (32) 
 
8 (29) 
 
0.205 
Subsequent child 
birth after index 
pregnancy, n (%) 
 
3 (11) 
 
13 (46) 
 
12 (43) 
 
0.008 
Change in body 
mass index since 
index pregnancy, 
kg/m2 
 
1.7 (1.0) 
 
0.5 (0.5) 
 
1.2 (0.5) 
 
0.471 
 
Data are presented as means ± standard deviations unless otherwise stated.  
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* Global analyses of difference between means, medians and proportions across the three groups were performed 
by ANOVA, Kruskal-Wallis or chi-square test, respectively.  
‡ Other comorbidities in the index pregnancy: asthma (n=7), thyroid diseases (n=4), migraine (n=3), multiple 
sclerosis (n=1), psoriasis (n=2), SLE (n=1), thrombophilia (n=1), depression (n=1). 
§ Any comorbidities at follow-up: hypertension (n=7), asthma (n=6), migraine (n=5), thyroid diseases (n=2), 
thrombophilia (n=3), multiple sclerosis (n=2), psoriasis (n=2), paroxysmal atrial fibrillation (n=1), SLE (n=1), 
bipolar disorder (n=1), depression (n=1). 
|| Daily antihypertensive / heart failure medications: angiotensin-converting enzyme (ACE) inhibitors, 
angiotensin II receptor antagonists, beta-blockers, calcium antagonists and diuretics. 
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Table S3. Clinical laboratory, electrocardiogram, additional exercise testing and cardiac magnetic 
imaging findings at study participation. 
 Peripartum 
cardiomyopathy 
Pre-eclampsia 
 
Controls 
 
P value*  
Laboratory blood 
and urine tests 
 
n=28 
 
n=28 
 
n=28 
 
Hemoglobin, 
mmol/L 
 
8.7 (0.8)‡ 
 
8.3 (0.5) 
 
8.3 (0.5) 
 
0.022 
Hemoglobin 1Ac, 
mmol/mol 
 
33.9 (4.0) 
 
34.2 (2.7) 
 
34.2 (2.7) 
 
0.926 
Cholesterol, 
mmol/L 
 
4.8 (1.3) 
 
4.8 (0.7) 
 
4.6 (0.8) 
 
0.665 
HDL-Cholesterol, 
mmol/L 
 
1.4 (0.6)† 
 
1.8 (0.4) 
 
1.7 (0.5) 
 
0.013 
LDL-Cholesterol, 
mmol/L 
 
3.1 (1.2) 
 
2.8 (0.6) 
 
2.7 (0.7) 
 
0.204 
Triglyceride, 
mmol/L 
 
1.4 (0.7)† 
 
1.0 (0.5) 
 
1.1 (0.7) 
 
0.009 
Creatinine, µmol/L 71.6 (16.1) 69.0 (10.0) 68.7 (9.3) 0.616 
Median NT-
ProBNP (range), 
pmol/L 
 
13.8 (5-188.0)†‡ 
 
6.8 (5-19.9) 
 
6.9 (5-91.8) 
 
0.015 
Urine albumin /     
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creatinine ratio, 
mg/g 
11.4 (21.2) 9.9 (19.0) 6.4 (23.4) 0.593 
Electrocardiogram 
at rest 
 
n=28 
 
n=28 
 
n=28 
 
Any ECG 
abnormality 
 
8 (29)‡ 
 
2 (7)§ 
 
0 
 
0.003 
Sinus rhythm 28 (100) 28 (100) 28 (100)  
PQ interval, ms  161 (25) 155 (19) 158  (26) 0.582 
QRS interval, ms 91 (11) 89 (7) 86 (6) 0.120 
Left ventricular 
hypertrophy 
 
5 (18) 
 
2 (7) 
 
0 
 
0.052 
Strain 1 (4) 0 0 0.364 
Negative T 2 (7) 0 0 0.129 
Exercise testing n=24 n=28 n=27  
Ventilatory 
efficiency, 
VE/VCO2 
 
23.2 (2.6) 
 
22.9 (3.4) 
 
23.6 (2.3) 
 
0.631 
Cardiac magnetic 
resonance imaging 
 
n=25 
 
n=27 
 
n=27 
 
Left ventricular parameters 
Cardiac index, 
l/min/m2 
 
3.5 (0.6) 
 
3.8 (0.5) 
 
3.5 (0.5) 
 
0.054 
Stroke volume, 
ml/m2 
 
52 (11) 
 
54 (7) 
 
53 (7) 
 
0.591 
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Left atrial volumes 
Left atrial minimal 
volume, ml/m2 
 
18 (9) 
 
18 (6) 
 
17 (6) 
 
0.902 
Left atrial maximal 
volume, ml/m2 
 
43 (14) 
 
46 (8) 
 
46 (7) 
 
0.691 
Left atrial mid-
diastolic volume, 
ml/m2  
 
30 (14) 
 
27 (6) 
 
26 (7) 
 
0.258 
Left atrial conduit 
volume, ml/m2 
 
27 (8) 
 
26 (6) 
 
24 (4) 
 
0.243 
Right ventricular parameters 
Right ventricular 
ejection fraction, % 
 
59 (7) 
 
61 (4) 
 
59 (4) 
 
0.425 
Right ventricular 
end-systolic 
volume, ml/m2 
 
33 (8) 
 
34 (1) 
 
36 (1) 
 
0.296 
Right ventricular 
end-diastolic 
volume, ml/m2 
 
82 (18) 
 
85 (12) 
 
88 (12) 
 
0.359 
 
Data are presented as means ± standard deviations unless otherwise stated.  
ECG, electrocardiogram. 
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* Global analyses of difference between means, medians and proportions across the three groups were performed 
by ANOVA, Kruskal-Wallis or chi-square test, respectively. A p value < 0.05 was considered statistical 
significant. 
† PPCM group significantly different compared with preeclampsia group. Post hoc analyses were performed by 
Student’s t test, Mann-Whitney test or chi-square test as appropriate. A p value < 0.05/3 = 0.0167 was 
considered statistical significant. 
‡ PPCM group significantly different compared with uncomplicated control group. Post hoc analyses were 
performed by Student’s t test, Mann-Whitney test or chi-square test as appropriate. A p value < 0.05/3 = 0.0167 
was considered statistical significant. 
§ Preeclampsia group significantly different compared with uncomplicated control group . Post hoc analyses 
were performed by Student’s t test, Mann-Whitney test or chi-square test as appropriate. A p value < 0.05/3 = 
0.0167 was considered statistical significant. 
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Figure S1. Example of time-volume curves constructed from the 25 left atrial (LA) volumes during one 
cardiac cycle with determination of specific volumes. 
A = minimal LA volume at the end of ventricular diastole (LAmin); B = maximal LA volume at the end of 
ventricular systole (LAmax); C = mid-diastolic LA volume after passive emptying of LA (LAmdv); D = LA 
volume immediately before LA contraction and active emptying (LAbac). The brighter curve illustrates a 
normal time-volume curve, and the darker curve is an example of diastolic dysfunction. LA emptying 
volumes that contributing to total LV filling were calculated as:  
LA passive emptying volume (LAPEV) = LAmax - LAmdv ; 
LA active emptying volume (LAAEV) = LAbac - LAmin; and 
LA conduit volume =  LVSV – (LAPEV + LAAEV) 
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LA passive emptying fraction (LAPEF) was calculated as: 
LAPEF = 100 x (LAmax- LAbac)/LAmax 
LA active emptying fraction (LAAEF) was calculated as 
LAAEF= 100 x (LAbac-LAmin)/LAbac. 
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